VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BIIBBiogen Inc.
$216.03$31.9B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksBIIBFinancials

Biogen Inc. (BIIB) Financials

30Y historyFree accessUpdated daily

Revenue growth remains inconsistent, fluctuating between a 7.1% contraction in 2025Q4 and a 7.3% expansion in 2025Q2, while gross margins have shown significant variance, dropping to 61.2% in 2024Q2 before recovering to 73.3% in 2026Q1.

BIIB Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue9.86B9.81B9.68B9.84B10.17B10.98B13.44B14.38B13.45B12.27B11.45B10.76B9.7B6.93B5.51B5.05B4.72B4.38B4.1B3.17B2.68B1.71B1.6B186.13M404.22M1.04B925.66M794.43M557.59M434.04M277.09M
Revenue Growth %0.42%1.39%-1.62%-3.32%-7.36%-18.32%-6.49%6.88%9.61%7.21%6.36%10.93%39.97%25.7%9.23%7.04%7.75%6.83%29.19%18.21%56.57%7.38%757.35%-53.95%-61.22%12.6%16.52%42.48%28.46%56.64%82.67%
Cost of Goods Sold2.98B2.9B2.31B2.53B2.28B2.11B1.81B1.96B1.82B1.63B1.43B1.24B1.17B857.7M545.49M466.78M400.26M382.1M401.99M335.19M274.38M373.61M554.32M284.74M1.46M136.51M125.2M111M74.51M50.19M28.52M
COGS % of Revenue-29.53%23.88%25.76%22.39%19.21%13.43%13.6%13.5%13.28%12.52%11.52%12.07%12.37%9.89%9.25%8.49%8.73%9.81%10.57%10.23%21.8%34.74%152.98%0.36%13.1%13.53%13.97%13.36%11.56%10.29%
Gross Profit6.88B6.91B7.37B7.3B7.9B8.87B11.64B12.42B11.64B10.64B10.02B9.52B8.53B6.07B4.97B4.58B4.32B4B3.7B2.84B2.41B1.34B1.04B-98.61M402.76M905.8M800.47M683.43M483.08M383.86M248.56M
Gross Margin %69.77%70.47%76.12%74.24%77.61%80.79%86.57%86.4%86.5%86.72%87.48%88.48%87.93%87.63%90.11%90.75%91.51%91.27%90.19%89.43%89.77%78.2%65.26%-52.98%99.64%86.9%86.47%86.03%86.64%88.44%89.71%
Gross Profit Growth %--6.14%0.87%-7.51%-11.01%-23.78%-6.3%6.75%9.33%6.27%5.17%11.62%40.46%22.24%8.46%6.16%8.03%8.11%30.29%17.76%79.75%28.66%1156.23%-124.48%-55.54%13.16%17.12%41.47%25.85%54.43%76.05%
Operating Expenses5.33B5.04B4.88B5.2B5.01B6.08B7.05B5.38B5.75B5.3B4.86B4.63B4.56B3.56B3.11B2.86B3.07B2.7B2.48B2.06B1.97B1.1B998.08M771.06M188.89M545.6M472.11M367.18M292.44M234.89M207.74M
OpEx % of Revenue-51.33%50.39%52.92%49.21%55.37%52.41%37.42%42.73%43.17%42.48%43.04%46.99%51.34%56.43%56.59%65.03%61.68%60.57%64.85%73.37%64.42%62.54%414.25%46.73%52.35%51%46.22%52.45%54.12%74.97%
Selling, General & Admin2.47B2.43B2.39B2.5B2.41B2.68B2.52B2.36B2.11B1.94B1.95B2.11B2.23B1.71B1.28B1.06B1.03B1.13B1.06B776.1M685.07M644.76M580.28M174.6M88.02M231.05M169.27M146.03M115.21M90.1M73.63M
SG&A % of Revenue-24.81%24.67%25.44%23.68%24.41%18.71%16.41%15.68%15.78%17.03%19.63%23.01%24.7%23.16%20.92%21.87%25.74%25.9%24.47%25.53%37.63%36.36%93.8%21.78%22.17%18.29%18.38%20.66%20.76%26.57%
Research & Development1.98B1.95B2.49B2.7B2.6B3.4B4.53B2.77B2.71B2.37B1.97B2.01B1.89B1.46B1.38B1.22B1.25B1.28B1.07B925.16M718.39M747.67M685.87M1.06B100.87M314.56M302.84M221.15M177.23M145.5M132.38M
R&D % of Revenue-19.92%25.72%27.48%25.53%30.97%33.7%19.27%20.14%19.34%17.24%18.7%19.51%21%25%24.16%26.47%29.31%26.16%29.17%26.78%43.63%42.98%567.51%24.95%30.18%32.72%27.84%31.78%33.52%47.78%
Other Operating Expenses2M647.7M00000250.5M929.2M988.1M940.7M506.5M434.2M391.1M0581.43M787.13M289.81M348.5M355.39M565.19M-288.46M-268.07M-459.87M00000-711K1.72M
Operating Income1.54B1.88B2.49B2.1B2.89B2.79B4.59B7.04B5.89B5.35B5.15B4.89B3.97B2.52B1.84B1.72B1.25B1.3B1.21B779.77M440.02M236.04M43.42M-869.67M213.88M360.2M328.36M316.25M190.64M148.97M40.83M
Operating Margin %15.65%19.14%25.74%21.32%28.4%25.42%34.16%48.98%43.77%43.55%45%45.44%40.94%36.29%33.34%34.16%26.48%29.59%29.62%24.59%16.4%13.77%2.72%-467.23%52.91%34.56%35.47%39.81%34.19%34.32%14.73%
Operating Income Growth %--24.61%18.74%-27.41%3.5%-39.22%-34.78%19.6%10.15%3.77%5.33%23.12%57.92%36.82%6.6%38.1%-3.59%6.74%55.64%77.21%86.42%443.67%104.99%-506.62%-40.62%9.7%3.83%65.89%27.97%264.86%448.41%
EBITDA2.43B2.81B3.16B2.59B3.41B3.28B5.05B7.51B6.54B6.07B5.79B5.49B4.61B3.05B2.2B2.08B1.6B1.72B1.68B1.16B815.89M638.25M482.85M-808.36M224.03M397.22M367.39M347.35M215.23M168.26M56.09M
EBITDA Margin %24.66%28.67%32.69%26.35%33.49%29.86%37.56%52.21%48.61%49.43%50.56%51.02%47.51%43.96%39.97%41.27%34.02%39.37%40.89%36.58%30.41%37.25%30.26%-434.29%55.42%38.11%39.69%43.72%38.6%38.77%20.24%
EBITDA Growth %-16%-11.08%22.04%-23.93%3.92%-35.07%-32.73%14.81%7.77%4.81%5.42%19.13%51.27%38.25%5.78%29.85%-6.89%2.85%44.45%42.18%27.83%32.18%159.73%-460.82%-43.6%8.12%5.77%61.39%27.91%199.97%205.5%
D&A (Non-Cash Add-back)888.7M935.4M673.2M494.8M518.4M487.7M457.2M464.7M650.5M721.6M637.2M600.4M637.2M531.7M365.65M358.93M355.74M427.96M462.06M380.29M375.87M402.21M439.44M61.31M10.16M37.02M39.03M31.1M24.59M19.3M15.26M
EBIT1.9B2.17B2.32B1.88B3.02B3.44B4.65B7.28B6.36B5.89B5.71B5.01B3.97B2.49B1.84B1.74B1.27B1.37B1.21B951.1M493.06M265.84M82.99M-865.44M247.59M393.45M491.42M316.25M190.64M148.97M40.83M
Net Interest Income-136.1M-158.2M-182.7M29.6M-157.3M-242.6M-180.5M-67.4M-88.1M-172.3M-196.6M-73.4M-17.3M-23.7M-7M-13.8M-13.8M12.7M20.1M63.1M100.3M53.1M38.33M18.43M18.45M40.17M38.66M0000
Interest Income139M87.8M67.6M276.5M89.3M11M42M120M112.5M78.5M63.4M22.1M12.2M8.2M29.5M19.2M22.3M48.5M72.1M103.6M101.22M62.75M57.23M33.61M33.72M44.13M42.97M0000
Interest Expense275.1M246M250.3M246.9M246.6M253.6M222.5M187.4M200.6M250.8M260M95.5M29.5M31.9M36.5M33M36.1M35.8M52M40.5M871K9.65M18.9M15.18M3.55M3.95M4.31M0000
Other Income/Expense-74.3M-476M-584.3M-800.5M705.3M-1.01B459.8M3.9M11M-217M-218.7M-136.2M-40.9M-52.2M12.1M-13.48M-18.98M37.25M-57.73M130.82M52.14M20.16M20.68M-10.96M17.65M29.3M158.75M12.77M19.55M00
Pretax Income1.47B1.4B1.91B1.3B3.59B1.78B5.05B7.05B5.9B5.13B4.93B4.75B3.93B2.46B1.85B1.71B1.23B1.33B1.16B910.6M492.16M256.19M64.09M-880.62M231.52M389.5M487.11M329.02M210.19M148.97M40.83M
Pretax Margin %14.89%14.29%19.7%13.18%35.33%16.21%37.58%49.01%43.85%41.79%43.09%44.17%40.52%35.53%33.56%33.89%26.08%30.44%28.21%28.71%18.34%14.95%4.02%-473.11%57.28%37.37%52.62%41.42%37.7%34.32%14.73%
Income Tax95.61M108.11M273.8M135.3M632.8M52.5M992.3M1.16B1.43B2.46B1.24B1.16B989.9M601M470.55M444.53M331.33M355.62M365.78M272.42M278.43M95.48M39.01M-5.53M83.43M116.81M153.53M108.57M71.5M59.8M299K
Effective Tax Rate %6.51%7.71%14.37%10.43%17.61%2.95%19.64%16.43%24.16%47.94%25.08%24.43%25.18%24.4%25.43%25.98%26.94%26.68%31.64%29.92%56.57%37.27%60.86%0.63%36.04%29.99%31.52%33%34.01%40.14%0.73%
Net Income1.37B1.29B1.63B1.16B3.05B1.56B4B5.89B4.43B2.54B3.7B3.55B2.93B1.86B1.38B1.23B1.01B970.13M783.17M638.17M217.51M160.71M25.09M-875.1M148.09M272.68M333.58M220.45M138.7M89.17M40.53M
Net Margin %13.92%13.18%16.87%11.81%29.95%14.17%29.76%40.96%32.93%20.69%32.34%32.95%30.25%26.86%25.02%24.45%21.31%22.16%19.11%20.12%8.11%9.38%1.57%-470.14%36.64%26.16%36.04%27.75%24.87%20.54%14.63%
Net Income Growth %-7.23%-20.76%40.57%-61.89%95.8%-61.1%-32.06%32.9%74.5%-31.43%4.39%20.86%57.59%34.95%11.8%22.8%3.62%23.87%22.72%193.4%35.34%540.64%102.87%-690.92%-45.69%-18.25%51.32%58.94%55.55%120%616.08%
Net Income (Continuing)1.37B1.29B1.63B1.16B2.96B1.73B4.06B5.89B4.47B2.67B3.7B3.59B2.94B1.86B01.27B898.57M977.06M790.11M638.17M213.73M160.71M25.09M-875.1M148.09M272.68M333.58M220.45M138.7M89.17M40.53M
Discontinued Operations000000000000000000003.78M0000000000
Minority Interest0000-9.5M63.5M-14.2M-4.1M-8M-14.7M-11.5M2.1M5.03M596K2.27M1.49M52.94M40.35M0000000000000
EPS (Diluted)9.258.8311.197.9720.8710.4024.8031.4221.5811.9216.9315.3412.377.815.765.043.943.352.651.990.630.470.07-2.620.500.680.720.470.150.100.04
EPS Growth %-7.8%-21.09%40.4%-61.81%100.67%-58.06%-21.07%45.6%81.04%-29.59%10.37%24.01%58.39%35.59%14.29%27.92%17.61%26.42%33.17%215.87%34.04%571.43%102.67%-624%-26.47%-5.56%53.19%213.33%55.93%119.13%-
EPS (Basic)-8.8511.208.0220.9710.4424.8631.4721.6211.9416.9615.3812.427.865.805.093.983.372.672.020.640.480.07-2.620.510.700.750.490.160.100.05
Diluted Shares Outstanding148.4M146.7M145.9M145.6M146M149.6M161.3M187.4M205.3M213M218.8M231.2M237.18M238.31M239.74M245.03M254.87M289.48M294.98M320.17M345.28M346.16M343.48M333.7M398.75M398.75M463.81M473.36M945.52M926.67M922.86M
Basic Shares Outstanding147.2M146.7M145.7M144.7M145.3M149.1M160.9M187.1M204.9M212.6M218.4M230.7M236.36M236.92M237.94M242.4M252.31M287.36M292.33M315.84M338.58M335.59M335M333.7M389.96M389.96M446.23M449.76M884.52M877.89M850M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetFortress
Cash FlowStable
Top Statement Risk

Neurology pipeline execution failure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Lacks Consistent Momentum

According to the provided quarterly data, Biogen's revenue growth remains inconsistent, fluctuating between a 7.1% contraction in 2025Q4 and a 7.3% expansion in 2025Q2, suggesting that the company is struggling to offset the secular decline of its legacy multiple sclerosis franchise with new product launches.

The top-line volatility indicates that the transition toward newer assets like Leqembi has yet to provide a stable growth floor. Investors should monitor whether the current revenue mix can sustain positive momentum as the legacy portfolio faces increasing generic pressure.

Gross Margin Volatility Reflects Complexity

As reported in financial statements, Biogen's gross margins have experienced significant variance, dropping to a low of 61.2% in 2024Q2 before recovering to 73.3% in 2026Q1, which highlights the sensitivity of the company's cost structure to product mix shifts and potential inventory-related adjustments.

The fluctuation in gross margins suggests that the company's manufacturing and collaboration-based cost structure is not yet optimized for its evolving product portfolio. This instability may indicate that the costs associated with newer therapies are currently less predictable than those of established legacy treatments.

Operating Leverage Remains Highly Variable

Based on the reported figures, Biogen's operating margins have swung from a negative 2.5% in 2025Q4 to a peak of 30.1% in 2025Q1, demonstrating that the company has yet to achieve consistent operating leverage as it balances R&D investment with necessary cost-cutting initiatives.

The lack of a clear trend in operating income relative to gross profit suggests that SG&A and R&D expenses are not scaling efficiently with revenue. This inconsistency warrants further investigation into whether management's restructuring programs are effectively controlling overhead or if they are merely reactive to trial outcomes.

Earnings Quality Impacted by Volatility

Data from the income statement shows that net income has fluctuated significantly, including a net loss in 2025Q4, which, when combined with consistent stock-based compensation expenses averaging over $70 million per quarter, suggests that reported EPS may not fully reflect the underlying operational cash generation.

The wide variance in net income appears driven by non-operating items and periodic adjustments rather than steady core performance. Investors should be cautious of relying on EPS as a proxy for operational health given the impact of collaboration accounting and potential one-time charges.

Structural Risks to Margin Sustainability

While the company maintains a strong balance sheet, the income statement reveals a concerning trend of margin compression during periods of high R&D spending, as seen in 2024Q4, which may indicate that the cost of innovation is currently outpacing the commercial returns of new assets.

Short-term margin pressure may be a structural reality rather than a temporary hurdle if the company's reliance on profit-sharing collaborations continues to dilute net margins. The market may be underestimating the long-term impact of these agreements on the company's ability to generate sustainable bottom-line growth.

BIIB — Frequently Asked Questions

Quick answers to the most common questions about buying BIIB stock.

What was Biogen Inc.'s (BIIB) revenue in 2025?

For fiscal year 2025, Biogen Inc. (BIIB) reported total revenue of $9.81B. This represents a 3440.6% increase compared to $277.1M in 1996.

Is Biogen Inc. (BIIB) profitable?

Biogen Inc. (BIIB) is profitable, generating $1.29B in net income for the fiscal year ending 2025 with a net profit margin of 13.2%.

What is Biogen Inc.'s operating profit margin?

Biogen Inc. (BIIB) reported an operating income of $1.88B, resulting in an operating profit margin of 19.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Biogen Inc.'s gross profit and gross margin?

Biogen Inc. (BIIB) generated $6.91B in gross profit for the year, representing a gross profit margin of 70.5%. This demonstrates the company's core pricing power and production efficiency.